MedPath

Latozinemab Advanced Drug Monograph

Published:Jun 19, 2025

Generic Name

Latozinemab

Drug Type

Biotech

Latozinemab (AL001): A Comprehensive Clinical and Scientific Review of a Progranulin-Elevating Monoclonal Antibody for the Treatment of Frontotemporal Dementia

I. Executive Summary

Latozinemab, also known by its development codes AL001 and GSK4527223, is an investigational, first-in-class humanized monoclonal antibody representing a novel immuno-neurology approach to treating neurodegenerative disease. Developed by Alector, Inc. in a major global collaboration with GSK, Latozinemab is designed to address the underlying genetic cause of a specific, devastating form of early-onset dementia: Frontotemporal Dementia with a progranulin gene (GRN) mutation (FTD-GRN). This condition is characterized by a haploinsufficiency of the progranulin (PGRN) protein, a critical regulator of lysosomal health and immune activity in the brain. Instead of attempting direct protein replacement, Latozinemab employs a sophisticated mechanism, targeting and inhibiting the sortilin (SORT1) receptor. SORT1 is the primary receptor responsible for the endocytosis and subsequent lysosomal degradation of PGRN. By blocking this pathway, Latozinemab effectively increases the half-life and circulating levels of endogenous PGRN.

The clinical development program for Latozinemab has systematically validated this therapeutic hypothesis. A Phase 1 study successfully demonstrated the drug's safety and, critically, established proof-of-mechanism by showing that Latozinemab administration restored deficient PGRN levels in the plasma and cerebrospinal fluid of FTD-GRN mutation carriers to the normal range observed in healthy volunteers. The subsequent open-label Phase 2 INFRONT-2 study provided further encouraging data. In symptomatic FTD-GRN patients, Latozinemab not only sustained normal PGRN levels but also led to the normalization of key downstream biomarkers of lysosomal dysfunction and neuroinflammation. Most significantly, exploratory clinical outcome data from this study suggested a 47% slowing in disease progression over 12 months compared to a matched external control cohort.

These promising results, combined with a favorable safety profile, have propelled Latozinemab into a pivotal, global Phase 3 trial, INFRONT-3. This randomized, double-blind, placebo-controlled study has completed enrollment and is designed to provide definitive evidence of Latozinemab's efficacy and safety, with topline data anticipated in the fourth quarter of 2025. The drug has received Orphan Drug, Fast Track, and Breakthrough Therapy designations from the U.S. Food and Drug Administration, underscoring the significant unmet medical need in FTD-GRN, a disease with no currently approved treatments.

Latozinemab is the most advanced candidate in a competitive FTD-GRN pipeline that features diverse therapeutic modalities, including gene therapies and small molecules. Its success in the INFRONT-3 trial would not only establish it as the standard of care for FTD-GRN but would also provide crucial validation for the broader strategy of targeting the progranulin pathway for neurodegenerative diseases, a strategy Alector and GSK are already pursuing with a follow-on molecule, AL101, for Alzheimer's and Parkinson's disease. The forthcoming data from INFRONT-3 represents a critical inflection point for Latozinemab, the FTD community, and the field of immuno-neurology.

II. The Pathophysiology of FTD-GRN: A Disease of Progranulin Haploinsufficiency

The Clinical Burden of Frontotemporal Dementia (FTD)

Frontotemporal dementia (FTD) is a devastating and rapidly progressive neurodegenerative disease that represents one of the most common causes of dementia in individuals under the age of 60.[1] It is characterized by the selective atrophy of the frontal and temporal lobes of the brain, regions responsible for complex cognitive processes such as personality, behavior, language, and executive function.[3] Unlike Alzheimer's disease, which primarily manifests as memory loss, the clinical presentation of FTD is dominated by profound changes in personality and social conduct, or by a progressive decline in language skills.[3]

The onset of symptoms typically occurs when individuals are in their 40s and 50s, a time of peak personal and professional productivity, leading to a significant burden on patients, families, and society.[3] The disease follows a relentless course, typically leading to death within 7 to 10 years of symptom onset.[3] Despite its severity and prevalence as a form of early-onset dementia, affecting an estimated 50,000 to 60,000 people in the United States and approximately 110,000 in the European Union, there are currently no U.S. Food and Drug Administration (FDA)-approved therapies that can slow or stop its progression.[2]

The Genetic Basis of FTD-GRN

A substantial portion of FTD cases are familial, indicating a strong genetic component.[9] Among the identified genetic causes, heterozygous loss-of-function mutations in the progranulin gene (

GRN) are one of the most common, accounting for 5% to 10% of all FTD cases and up to 26% of familial FTD cases.[3]

These mutations lead to a condition known as progranulin haploinsufficiency. In affected individuals, one of the two copies of the GRN gene is non-functional, resulting in the production of approximately 50% of the normal amount of the progranulin (PGRN) protein.[5] This deficiency is not merely a risk factor; it is directly causative of the disease, with a penetrance exceeding 90%, meaning that the vast majority of individuals who inherit a pathogenic

GRN mutation will develop FTD.[10] This clear, monogenic cause-and-effect relationship provides a precise and validated target for therapeutic intervention.

The Biology of Progranulin (PGRN) and Its Role in Neuronal Health

Progranulin is a multifaceted, secreted glycoprotein that plays a critical role in maintaining the health of the central nervous system.[9] In the brain, it is expressed by several cell types, most notably mature neurons and microglia, the resident immune cells of the CNS.[4] Its functions are pleiotropic, encompassing key processes such as neuronal survival, neurite outgrowth, and, crucially, the regulation of lysosomal function and neuroinflammation.[10]

A growing body of evidence has established PGRN as an essential regulator of lysosomal health. Lysosomes are cellular organelles responsible for the degradation and recycling of cellular waste, and their proper function is vital for neuronal homeostasis. PGRN is trafficked to the lysosome, where it is processed into smaller peptides known as granulins.[17] Within this compartment, PGRN and its derivatives are critical for maintaining the function of key lysosomal enzymes, such as glucocerebrosidase (GCase), and regulating lysosomal biogenesis and acidification.[16]

Consequently, PGRN deficiency, as seen in FTD-GRN, leads to profound lysosomal dysfunction. This is evidenced by the pathological accumulation of cellular waste products, including specific lysosomal lipids like bis(monoacylglycero)phosphate (BMP) and glucosylsphingosine, and the formation of lipofuscin aggregates, a hallmark of cellular aging and stress.[17] Furthermore, PGRN plays a pivotal anti-inflammatory role in the brain. It regulates the activation state of microglia, and its absence leads to an exacerbated neuroinflammatory response, characterized by increased production of pro-inflammatory cytokines.[18] This combination of lysosomal dysfunction and chronic neuroinflammation, driven by PGRN haploinsufficiency, is believed to be the central mechanism driving the progressive neurodegeneration observed in FTD-GRN patients.

The Degradation Pathway: Sortilin (SORT1) as the Key Regulator

The therapeutic challenge in FTD-GRN is to restore PGRN levels in the brain. While direct administration of recombinant PGRN protein might seem like the most straightforward approach, it is technically challenging due to the protein's short half-life and difficulty in manufacturing.[24] A more viable strategy emerged from the discovery of the primary pathway responsible for PGRN clearance.

Unbiased expression cloning and subsequent cellular biology studies identified the neuronal receptor sortilin (SORT1) as the principal regulator of extracellular PGRN levels.[10] The mechanism involves the high-affinity binding of PGRN, via its C-terminal domain, to SORT1 on the surface of neurons and other cells.[26] This binding event triggers the rapid endocytosis of the PGRN-SORT1 complex, which is then trafficked to the lysosome for degradation.[10]

This SORT1-mediated degradation pathway is not a minor contributor but a primary determinant of PGRN concentration in both plasma and cerebrospinal fluid (CSF).[10] This was definitively demonstrated in studies using mice genetically engineered to lack the

Sort1 gene; these mice exhibited a 2.5- to 5-fold increase in their brain and serum PGRN levels.[27] Critically, when this

Sort1 knockout was crossed with a mouse model of FTD-GRN (which has 50% of normal PGRN), the resulting offspring had their PGRN levels fully restored to normal or even higher levels.[27]

This pivotal discovery illuminated a clear and druggable therapeutic strategy. Rather than attempting to supply exogenous PGRN, one could "plug the drain" by blocking the SORT1-PGRN interaction. This would inhibit the natural clearance mechanism, thereby increasing the half-life and steady-state concentration of the patient's own endogenously produced PGRN. This insight forms the fundamental scientific rationale for the development of Latozinemab.

III. Latozinemab: A Targeted Immuno-Neurology Approach

Latozinemab is the clinical embodiment of the therapeutic strategy to elevate progranulin levels by inhibiting the SORT1 degradation pathway. It represents a targeted immuno-neurology approach, leveraging a monoclonal antibody to modulate a key biological process implicated in the pathogenesis of FTD-GRN.

PropertyDescription
International Nonproprietary Name (INN)Latozinemab
Development CodesAL001, GSK4527223
Drug TypeBiotech, Humanized Recombinant Monoclonal Antibody (IgG1)
TargetSortilin (SORT1) Receptor
Mechanism of ActionBinds to the SORT1 receptor, blocking the PGRN-SORT1 interaction and inhibiting SORT1-mediated endocytosis and degradation of PGRN. This action increases the circulating half-life of PGRN, leading to elevated levels in the plasma and central nervous system.
Lead IndicationFrontotemporal Dementia with a GRN mutation (FTD-GRN)
DevelopersAlector, Inc. in collaboration with GSK
Route of AdministrationIntravenous (IV) Infusion
Table 1: Summary of Latozinemab (AL001) Profile 3

Mechanism of Action in Detail

Latozinemab is a humanized monoclonal antibody of the IgG1 subclass, specifically engineered to bind with high affinity to the human sortilin receptor.[10] Its mechanism is precise and multifaceted.

In vitro assays have confirmed that Latozinemab binding to SORT1 effectively blocks the subsequent interaction between PGRN and the receptor.[10] This steric hindrance is the primary mode of action.

Furthermore, the binding of Latozinemab to SORT1 on the cell surface leads to a dose-dependent downregulation of the receptor itself.[10] By preventing PGRN from binding to its clearance receptor and reducing the number of available receptors on the cell surface, Latozinemab effectively shuts down the principal pathway for PGRN degradation. The direct consequence is an increase in the half-life of PGRN in circulation, allowing its concentration to rise in both the plasma and, critically, the cerebrospinal fluid, thereby restoring the levels of this vital neurotrophic and anti-inflammatory factor within the CNS.[3]

Corporate Development: The Alector and GSK Global Collaboration

The clinical and commercial potential of Latozinemab and the broader progranulin-elevating strategy attracted significant interest from major pharmaceutical companies. In July 2021, Alector entered into a landmark global collaboration and license agreement with GSK to co-develop and co-commercialize its progranulin franchise. This partnership encompasses both Latozinemab (AL001) and AL101, a second-generation anti-SORT1 antibody with distinct pharmacokinetic properties being developed for more prevalent neurodegenerative diseases like Alzheimer's and Parkinson's disease.[3]

The terms of the agreement were substantial, reflecting strong conviction in the platform. Alector received $700 million in upfront payments and is eligible for up to an additional $1.5 billion in clinical, regulatory, and commercial milestone payments.[3] The commercialization structure is a 50/50 profit-and-loss share in the United States, with Alector receiving double-digit tiered royalties on sales outside the U.S..[3]

This collaboration represents a critical validation of Alector's immuno-neurology platform. For a clinical-stage biotechnology company, such a partnership significantly de-risks the enormous financial investment required for late-stage global clinical trials and commercial launch. It provides Alector with the resources and global footprint of a major pharmaceutical partner, enabling an acceleration of the development program. This allows for the parallel pursuit of multiple indications for the progranulin franchise, a strategy that would be untenable for a smaller company alone, thereby maximizing the potential of the therapeutic approach.[36]

IV. Clinical Development Program: From Proof-of-Concept to Pivotal Trial

The clinical development of Latozinemab has followed a logical and systematic path, progressing from initial safety and proof-of-mechanism studies to a large-scale, pivotal Phase 3 trial designed for regulatory approval.

Phase 1 First-in-Human Study (NCT03636204)

The initial foray into human testing was a Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Latozinemab. The study enrolled healthy volunteers as well as both asymptomatic and symptomatic carriers of a pathogenic GRN mutation.[10]

The results of this trial were highly successful and foundational for the program's advancement. First, the drug was found to have a favorable safety and tolerability profile, a prerequisite for any further development.[10] Second, and most importantly, the study provided clear proof-of-mechanism. Administration of Latozinemab resulted in a rapid, dose-dependent, and sustained increase in PGRN levels in both plasma and CSF. In FTD-GRN mutation carriers, whose baseline PGRN levels are approximately 50% of normal, Latozinemab treatment successfully restored these levels to the range observed in healthy volunteers.[10] This confirmed that targeting SORT1 was a viable strategy to reverse the progranulin haploinsufficiency that causes the disease.

Phase 2 INFRONT-2 Open-Label Study (NCT03987295)

Building on the Phase 1 success, the INFRONT-2 study was initiated as an open-label trial to assess the long-term safety and to explore a suite of biomarkers and clinical outcomes over a 96-week period. The study enrolled three distinct patient cohorts: asymptomatic FTD-GRN carriers, symptomatic FTD-GRN patients, and symptomatic FTD-C9orf72 patients.[1] The inclusion of the FTD-C9orf72 cohort was designed to explore the potential of PGRN elevation in a related but genetically distinct form of FTD that also features TDP-43 pathology.

FTD-GRN Cohort Results

The data from the symptomatic FTD-GRN cohort (up to 12 patients) provided compelling evidence of biological activity and preliminary signs of clinical efficacy.

Biomarker Response: Treatment with Latozinemab not only sustained the normalization of PGRN levels in plasma and CSF for over a year but also had a measurable impact on downstream biomarkers of pathology. Levels of lysosomal proteins like cathepsin D (CTSD) and lysosomal-associated membrane protein 1 (LAMP1), which are elevated in FTD-GRN, trended down towards normal levels. Similarly, biomarkers of neuroinflammation and astrogliosis, such as complement C1q B chain (C1QB) and glial fibrillary acidic protein (GFAP), also showed a durable decrease. In contrast, levels of neurofilament light chain (NfL), a marker of ongoing axonal damage, remained stable, suggesting a potential attenuation of active neurodegeneration.[44]

Biomarker (Fluid)Baseline (Mean, SE)12 Months (Mean, SE)Healthy Control RangeChange
PGRN (Plasma, ng/mL)40.3 (2.64)86.8 (3.72)64.6 – 196.0Restored to Normal
PGRN (CSF, ng/mL)2.3 (0.22)4.2 (0.54)3.48 – 7.06Restored to Normal
CTSD (CSF, fmol/L)5.2 (1.16)3.1 (0.21)3.4 (0.08)Normalized
LAMP1 (CSF, fmol/L)0.6 (0.12)0.4 (0.04)0.4 (0.01)Normalized
C1QB (CSF, fmol/L)0.7 (0.12)0.5 (0.02)0.5 (0.02)Normalized
NfL (Plasma, pg/mL)62.8 (13.57)46.3 (12.93)-Stable
NfL (CSF, ng/mL)7.3 (1.51)6.5 (1.29)-Stable
Table 2: Key Biomarker Results from the INFRONT-2 FTD-GRN Cohort (12 Months) 45

Clinical Outcome Data: While INFRONT-2 was a small, open-label study not powered for definitive efficacy, the investigators included an exploratory analysis comparing the clinical progression of the treated patients to an external control cohort. Using the Clinical Dementia Rating (CDR®) plus the National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (NACC FTLD-SB) scale, a validated tool for measuring FTD severity, the analysis provided a tantalizing first look at potential clinical benefit.

CohortNAnnualized Change in CDR® plus NACC FTLD-SB
Latozinemab (INFRONT-2)12+3.4 points
Matched Control (GENFI2)10+6.4 points
Difference (Slowing of Progression)-3.0 points (47%)
Table 3: Clinical Outcome Data (CDR® plus NACC FTLD-SB) from INFRONT-2 vs. Matched Controls (12 Months) 45

The results suggested that treatment with Latozinemab slowed the rate of clinical decline by 47% over one year compared to matched, untreated patients from the Genetic FTD Initiative (GENFI2) registry.[44]

FTD-C9orf72 Cohort Results

In the FTD-C9orf72 cohort, Latozinemab treatment also successfully elevated PGRN levels in plasma and CSF.[1] An initial analysis at the 2022 AD/PD conference, comparing the treated group to a matched control cohort from the ALLFTD registry, suggested a similar trend toward slowed progression.[1] However, a subsequent analysis presented at the 2023 CTAD conference with full 12-month data found no significant impact on the rate of disease progression in this cohort, despite the sustained elevation of PGRN.[46]

This divergence in outcomes is a crucial finding. It strongly suggests that while elevating PGRN may have broad neuro-supportive effects, its ability to be truly disease-modifying is most pronounced when PGRN deficiency is the direct, underlying cause of the disease, as is the case in FTD-GRN. This result provided a clear strategic rationale for focusing the pivotal Phase 3 development specifically on the FTD-GRN population, where the therapeutic hypothesis is most direct and the probability of success is highest.

Phase 3 INFRONT-3 Pivotal Study (NCT04374136)

The INFRONT-3 trial is the ongoing, global, pivotal study designed to provide the definitive evidence of Latozinemab's efficacy and safety required for regulatory approval.

ParameterDetails
Study TitleA Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Phase3
StatusActive, Not Recruiting (Enrollment complete as of October 2023)
SponsorAlector, Inc. (in collaboration with GSK)
InterventionsLatozinemab 60 mg/kg IV every 4 weeks vs. Placebo IV every 4 weeks
Randomization3:2 (Latozinemab:Placebo)
PopulationSymptomatic and at-risk individuals (aged 25-85) with a heterozygous loss-of-function GRN mutation.
Enrollment119 participants (103 symptomatic, 16 at-risk)
Duration96-week double-blind treatment period, followed by a 96-week open-label extension (OLE)
Primary EndpointChange from baseline in the Clinical Dementia Rating (CDR®) plus NACC FTLD-SB score
Key Secondary & Exploratory EndpointsClinical Global Impression (CGI-S, CGI-I), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Frontotemporal Lobar Degeneration Rating Scale (FRS), blood and CSF biomarkers (NfL, GFAP, PGRN), and volumetric MRI (vMRI)
Table 4: INFRONT-3 (NCT04374136) Pivotal Trial Design Summary 6

The study's design is robust, employing a randomized, double-blind, placebo-controlled framework to minimize bias.[8] The choice of the CDR® plus NACC FTLD-SB as the primary endpoint is significant, as it is a validated instrument that captures cognitive, functional, behavioral, and language domains, and has been accepted by both the FDA and the European Medicines Agency (EMA) as a suitable primary endpoint for FTD-GRN trials.[6]

The trial successfully enrolled a representative patient population, including both symptomatic individuals across a spectrum of disease severity (Global CDR scores from 0.5 to 2) and a cohort of at-risk, presymptomatic individuals (Global CDR score of 0).[8] Baseline characteristics presented at major neurology conferences in 2024 and 2025 confirmed that the demographics and disease metrics of the enrolled population are consistent with those observed in large FTD-GRN patient registries, ensuring the trial's results will be generalizable to the real-world patient population.[6]

Latozinemab has been granted multiple designations by the FDA that are intended to expedite the development and review of drugs for serious conditions with high unmet need, including Orphan Drug, Fast Track, and, most recently, Breakthrough Therapy Designation, the last of which was based on the encouraging Phase 2 data.[3] With enrollment completed in October 2023, the 96-week treatment period is ongoing, and Alector and GSK have consistently guided that topline data are expected in the fourth quarter of 2025.[12]

Expanded Access and Long-Term Extension

Alector has established an open-label extension (OLE) and a continuation study for participants who complete the 96-week blinded portion of the INFRONT-3 trial.[8] This allows for the collection of valuable long-term safety and efficacy data while providing continued access to the investigational therapy for trial participants. At present, in line with common industry practice for companies focused on completing pivotal trials necessary for regulatory approval, Alector does not have a broader expanded access or compassionate use program open to the general public.[66]

V. Competitive and Market Landscape

Latozinemab is the clear frontrunner in the race to develop a therapy for FTD-GRN, but it is not alone. The field is populated by a range of innovative therapeutic modalities, each with distinct potential advantages and disadvantages.

The FTD-GRN Therapeutic Pipeline: A Race of Diverse Modalities

The primary therapeutic strategies being pursued for FTD-GRN aim to restore progranulin levels through different means: antibody-mediated inhibition of degradation, gene therapy to replace the faulty GRN gene, direct protein replacement, and small molecules to enhance PGRN expression or inhibit its degradation.

Company (Developer/Partner)Drug CandidateModalityTarget/MechanismHighest Development Stage
Alector / GSKLatozinemab (AL001)Monoclonal AntibodyInhibits SORT1 receptorPhase 3
Prevail Therapeutics / Eli LillyPR006 (LY3884963)AAV9 Gene TherapyGRN gene replacementPhase 1/2
Passage BioPBFT02AAV1 Gene TherapyGRN gene replacementPhase 1/2
Denali Therapeutics / TakedaDNL593 (TAK-594)Protein Replacement (TV)PGRN delivery across BBBPhase 1/2
Arkuda Therapeutics / J&JARKD-104Small MoleculePGRN enhancerPhase 1
Vesper BioVES001Small MoleculeSortilin inhibitorPhase 1b/2a
Table 5: Competitive Landscape of Progranulin-Enhancing Therapies for FTD-GRN 30

Latozinemab's primary advantage is its lead in clinical development, being the only candidate currently in a pivotal Phase 3 trial.[47] However, gene therapies from Prevail/Lilly and Passage Bio offer the potential for a one-time, durable treatment, which could be a significant advantage over a chronically administered intravenous infusion.[71] Small molecule approaches from Arkuda/J&J and Vesper Bio could offer the convenience of oral administration.[30] Denali's innovative approach uses a "Transport Vehicle" (TV) technology to shuttle the PGRN protein itself across the blood-brain barrier, representing a novel form of protein replacement therapy.[69] The success and safety profiles of these different modalities in early-stage trials will determine the long-term competitive dynamics.

Market Analysis and Forecasts

The market for FTD, while comprised of rare disease subtypes, represents a significant unmet need. The overall FTD market in the seven major markets (7MM: US, EU4, UK, Japan) was estimated at $142.8 million in 2024, with projections to grow to $688.2 million by 2035, largely driven by the approval of new, targeted therapies.[91]

FTD-GRN constitutes a specific, genetically-defined sub-population. It accounts for 5-10% of the total FTD patient pool, which is estimated to be 50,000-60,000 individuals in the U.S. and around 110,000 in the European Union.[3] This translates to a target population of approximately 3,000 to 6,000 patients in the United States, classifying it as an ultra-orphan indication.[23]

Despite the small patient population, the commercial potential is significant due to the complete lack of approved treatments and the severity of the disease, which can support premium pricing. Analyst forecasts predict a potential 2025 launch for Latozinemab, should the INFRONT-3 trial be successful. These reports project a rapid uptake, with a probability-adjusted peak market share of approximately 60%, achieved within five years of launch.[92]

Alector is well-capitalized to see the program through its pivotal data readout and beyond. Bolstered by the GSK collaboration, the company has reported a cash runway extending into the second half of 2027, providing financial stability through this critical period.[58]

The ultimate commercial success of the progranulin franchise, however, likely hinges on expanding beyond the FTD-GRN niche. The development of AL101, a follow-on antibody with a similar mechanism but different PK/PD properties, for the vastly larger markets of Alzheimer's disease and Parkinson's disease is a key component of Alector and GSK's long-term strategy.[12] Genetic evidence links moderately reduced PGRN levels to an increased risk for these more common neurodegenerative disorders. A successful outcome for Latozinemab in FTD-GRN would provide powerful validation for this broader therapeutic hypothesis, making it a critical first step in a much larger strategic vision.

VI. Expert Analysis and Forward Look

A comprehensive evaluation of Latozinemab reveals a well-designed therapeutic candidate with a strong biological rationale, advancing through a logical clinical development pathway. Its future, however, rests almost entirely on the outcome of the ongoing pivotal INFRONT-3 trial.

Synthesis of Evidence (SWOT Analysis)

  • Strengths: The program is built on a compelling and genetically validated biological rationale. The mechanism of action is clear and has been unequivocally demonstrated with biomarker data from Phase 1 and 2 trials, which showed restoration of PGRN levels and normalization of downstream pathological markers. As the only candidate in Phase 3, Latozinemab has a significant first-mover advantage. The program is supported by a robust global partnership with GSK and has received multiple favorable regulatory designations from the FDA, which could expedite its path to market.
  • Weaknesses: The most compelling evidence of clinical efficacy to date comes from a small, open-label Phase 2 study compared against an external control group. While encouraging, these results carry inherent limitations and must be replicated in the larger, placebo-controlled INFRONT-3 trial to be considered definitive. The intravenous route of administration every four weeks is less convenient than potential future oral or one-time gene therapy options. Furthermore, the lack of clear clinical benefit in the FTD-C9orf72 cohort limits the immediate potential for label expansion beyond the FTD-GRN niche.
  • Opportunities: A successful INFRONT-3 trial would position Latozinemab as the first-ever approved, disease-modifying therapy for FTD-GRN, a field with an enormous unmet medical need. This would establish a dominant clinical and commercial foothold. More broadly, a positive outcome would serve as powerful validation for Alector's immuno-neurology platform and the entire progranulin-elevating therapeutic strategy, significantly de-risking the development of the follow-on molecule, AL101, for the much larger Alzheimer's and Parkinson's disease markets.
  • Threats: The primary threat is the failure of the INFRONT-3 trial to meet its primary endpoint with a clinically meaningful effect size. The competitive landscape, though currently behind, is dynamic. The emergence of a more convenient (oral small molecule) or more durable (one-time gene therapy) treatment with a comparable or superior efficacy and safety profile could erode Latozinemab's market share in the long term.

Key Questions for INFRONT-3

The topline data release for INFRONT-3, expected in Q4 2025, will be a watershed moment for the program. The key questions that these data must answer are:

  1. Efficacy Replication: Will the 47% slowing of clinical progression observed in the INFRONT-2 cohort be replicated in the larger, more rigorous, placebo-controlled setting of INFRONT-3? The magnitude and statistical significance of the treatment effect on the CDR® plus NACC FTLD-SB primary endpoint will be the single most important determinant of the drug's future.
  2. Clinical Meaningfulness: Beyond statistical significance, will the observed effect size be deemed clinically meaningful by physicians, patients, and payers? In a fatal, progressive disease with no options, even a modest but consistent slowing of decline could be considered highly valuable.
  3. Long-Term Safety: Will the favorable safety profile observed in shorter-term studies hold over the full 96-week treatment period? The absence of new or concerning safety signals will be critical for a positive risk-benefit assessment.
  4. Preventative Potential: What will the data from the at-risk, presymptomatic cohort show? While likely not powered for a primary efficacy claim, any signal that Latozinemab can delay or prevent the onset of symptoms in this population would be a monumental finding for the field of neurodegeneration and would dramatically expand the drug's long-term potential.

Future Directions and Concluding Remarks

Latozinemab stands at the precipice of potentially transforming the treatment landscape for FTD-GRN. Alector and GSK have executed a well-designed development program founded on strong science, culminating in the pivotal INFRONT-3 trial. The outcome of this trial will have profound implications, not only for the FTD community who are in desperate need of a therapy, but also for the broader field of neurodegenerative disease research.[7]

Success would establish Latozinemab as the standard of care and provide immense hope. It would also validate the targeting of the SORT1/PGRN axis, catalyzing further investment and research into this pathway. The long-term strategic vision for Alector and GSK clearly extends beyond FTD-GRN. The development of AL101 for Alzheimer's and Parkinson's disease represents a calculated, lifecycle management strategy designed to leverage the progranulin-elevating mechanism in patient populations orders of magnitude larger than FTD-GRN.[12] The success of Latozinemab is the critical first step and the necessary proof-of-concept for this ambitious and potentially revolutionary therapeutic franchise. All eyes in the neurology community now turn to the anticipated data readout in late 2025.

Works cited

  1. Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial - GlobeNewswire, accessed June 19, 2025, https://www.globenewswire.com/news-release/2022/03/15/2403328/0/en/Alector-Presents-AL001-latozinemab-Data-from-the-FTD-C9orf72-Cohort-of-the-INFRONT-2-Phase-2-Clinical-Trial.html
  2. Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations, accessed June 19, 2025, https://www.prevailtherapeutics.com/prevail-therapeutics-announces-first-patient-dosed-in-phase-1-2-proclaim-clinical-trial-evaluating-pr006-for-the-treatment-of-frontotemporal-dementia-patients-with-grn-mutations/
  3. FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) - GlobeNewswire, accessed June 19, 2025, https://www.globenewswire.com/news-release/2024/02/07/2825041/0/en/FDA-Grants-Latozinemab-Breakthrough-Therapy-Designation-for-Frontotemporal-Dementia-Due-to-a-Progranulin-Gene-Mutation-FTD-GRN.html
  4. Frontotemporal Dementia (FTD) - Alector, accessed June 19, 2025, https://alector.com/patients/frontotemporal-dementia-ftd/
  5. Frontotemporal Dementia (FTD) - Passage Bio, accessed June 19, 2025, https://www.passagebio.com/pipeline/frontotemporal-dementia-1/default.aspx
  6. Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024), accessed June 19, 2025, https://investors.alector.com/news-releases/news-release-details/alector-presents-baseline-characteristics-pivotal-infront-3/
  7. GRN Frontotemporal Dementia - GeneReviews® - NCBI Bookshelf, accessed June 19, 2025, https://www.ncbi.nlm.nih.gov/books/NBK1371/
  8. Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) | ALEC Stock News, accessed June 19, 2025, https://www.stocktitan.net/news/ALEC/alector-presents-baseline-characteristics-for-pivotal-infront-3-d60lk4dor42j.html
  9. Frontotemporal dementia non-sense mutation of progranulin rescued by aminoglycosides, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7068117/
  10. Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementia - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10865485/
  11. Prevail Therapeutics Announces FDA Orphan Drug Designation Granted to PR006 for the Treatment of Patients with Frontotemporal Dementia with a GRN Mutation, accessed June 19, 2025, https://www.prevailtherapeutics.com/wp-content/uploads/2021/01/Prevail-Therapeutics-Announces-FDA-Orphan-Drug-Designation-Granted-to-PR006-for-the-Treatment-of-Patients-with-Frontotemporal-Dementia-with-a-GRN-Mutation.pdf
  12. Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025, accessed June 19, 2025, https://investors.alector.com/news-releases/news-release-details/alector-reports-recent-progress-and-outlines-strategic/
  13. FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) - Investors | Alector, accessed June 19, 2025, https://investors.alector.com/news-releases/news-release-details/fda-grants-latozinemab-breakthrough-therapy-designation/
  14. LATOZINEMAB (AL001) Market Forecast LATOZINEMAB (AL001) drug Insight - DelveInsight, accessed June 19, 2025, https://www.delveinsight.com/report-store/latozinemab-al001-emerging-drug-insight-and-market-forecast
  15. Latozinemab - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 19, 2025, https://synapse.patsnap.com/drug/f65899fa24204cac8fd94f5bdcf9c91f
  16. Progranulin regulates lysosomal function and biogenesis through ..., accessed June 19, 2025, https://academic.oup.com/hmg/article/26/5/969/2877880
  17. Granulins rescue inflammation, lysosome dysfunction, lipofuscin, and neuropathology in a mouse model of progranulin deficiency - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/39565694/
  18. Progranulin – Marker of Neuroinflammation | Biomol Blog | Resources, accessed June 19, 2025, https://www.biomol.com/resources/biomol-blog/progranulin-marker-of-neuroinflammation
  19. Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease, accessed June 19, 2025, https://investors.alector.com/news-releases/news-release-details/alector-announces-completion-enrollment-progress-ad-phase-2/
  20. Pipeline for Neurodegenerative Diseases - Alector, accessed June 19, 2025, https://www.alector.com/pipeline/
  21. Alzheimer's Disease - Alector, accessed June 19, 2025, https://alector.com/patients/alzheimers-disease-ad/
  22. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/34450028/
  23. Computationally designed therapy targeting lysosomal function and inflammation in neurodegenerative diseases | Q-FASTR, accessed June 19, 2025, https://qfastr.hms.harvard.edu/qfr/computationally-designed-therapy-targeting-lysosomal-function-and-inflammation
  24. Small business spotlight: Alector generates hope for treating neurodegeneration, accessed June 19, 2025, https://www.nia.nih.gov/news/small-business-spotlight-alector-generates-hope-treating-neurodegeneration
  25. pmc.ncbi.nlm.nih.gov, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10865485/#:~:text=In%20vitro%2C%20latozinemab%20effectively%20binds,blocks%20the%20sortilin%E2%80%93PGRN%20interaction.
  26. Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency - Mayo Clinic, accessed June 19, 2025, https://www.mayo.edu/research/documents/chris-poster-for-rna-meeting/doc-20087749
  27. Sortilin-Mediated Endocytosis Determines Levels of the Fronto ..., accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2990962/
  28. Reshaping the progranulin/sortilin interaction for targeted degradation of extracellular proteins | bioRxiv, accessed June 19, 2025, https://www.biorxiv.org/content/10.1101/2025.03.03.641244v1
  29. Targeted manipulation of the sortilin–progranulin axis rescues progranulin haploinsufficiency - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3929086/
  30. Vesper Bio Clinical Trial for FTD-GRN Treatment Achieves Enrollment Milestone | AFTD, accessed June 19, 2025, https://www.theaftd.org/posts/1ftd-in-the-news/b-vesper-bio-ftd-grn-update625/
  31. Latozinemab Treatment for Dementia - Ontosight.ai, accessed June 19, 2025, https://ontosight.ai/glossary/term/latozinemab-treatment-for-dementia--67a2cc28c445bf945af631a5
  32. Latozinemab (AL001) | Anti-Sortilin Antibody - MedchemExpress.com, accessed June 19, 2025, https://www.medchemexpress.com/latozinemab.html
  33. Latozinemab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed June 19, 2025, https://go.drugbank.com/drugs/DB16978
  34. (PDF) Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia, accessed June 19, 2025, https://www.researchgate.net/publication/371605045_Latozinemab_a_novel_progranulin-elevating_therapy_for_frontotemporal_dementia
  35. Alector Reports Third Quarter 2021 Financial Results - SEC.gov, accessed June 19, 2025, https://www.sec.gov/Archives/edgar/data/1653087/000095017021003064/alec-ex99_1.htm
  36. With GSK, Alector has the Big Pharma backing to capitalize on a big moment in Alzheimer's drug development | Fierce Biotech, accessed June 19, 2025, https://www.fiercebiotech.com/biotech/gsk-alector-has-big-pharma-backing-to-capitalize-a-big-moment-alzheimer-s-drug-development
  37. Alector Completes Enrollment for Phase II Trial of Investigational Alzheimer's Disease Therapy, accessed June 19, 2025, https://www.appliedclinicaltrialsonline.com/view/alector-enrollment-phaseii-trial-investigational-alzheimers-disease-therapy
  38. Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025, accessed June 19, 2025, https://www.globenewswire.com/news-release/2025/01/13/3008414/0/en/Alector-Reports-on-Recent-Progress-and-Outlines-Strategic-Priorities-for-2025.html
  39. Latozinemab Completed Phase 1 Trials for Frontal Temporal Dementia (FTD) / Healthy Lifestyle Behaviors Treatment - DrugBank, accessed June 19, 2025, https://go.drugbank.com/drugs/DB16978/clinical_trials?conditions=DBCOND0069563%2CDBCOND0059969&phase=1&purpose=treatment&status=completed
  40. Healthy Volunteers Completed Phase 1 Trials for Latozinemab (DB16978) - DrugBank, accessed June 19, 2025, https://go.drugbank.com/indications/DBCOND0028122/clinical_trials/DB16978?phase=1&status=completed
  41. Phase 1 study of latozinemab in progranulin-associated frontotemporal dementia - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/38356474/
  42. Phase 1 study of latozinemab in progranulin-associated frontotemporal dementia, accessed June 19, 2025, https://www.researchgate.net/publication/378231355_Phase_1_study_of_latozinemab_in_progranulin-associated_frontotemporal_dementia
  43. Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial, accessed June 19, 2025, https://investors.alector.com/news-releases/news-release-details/alector-presents-al001-latozinemab-data-ftd-c9orf72-cohort/
  44. Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study, accessed June 19, 2025, https://investors.alector.com/news-releases/news-release-details/alector-presents-encouraging-new-al001-data-symptomatic-ftd-grn/
  45. Alector Presents 12-Month Results from the INFRONT-2 Phase, accessed June 19, 2025, https://www.globenewswire.com/news-release/2021/07/29/2271495/0/en/Alector-Presents-12-Month-Results-from-the-INFRONT-2-Phase-2-Open-label-Clinical-Study-of-AL001-for-the-Treatment-of-Symptomatic-Frontotemporal-Dementia-Patients-with-a-Progranulin.html
  46. Latozinemab Shows No Impact on Disease Progression in C9orf72 Frontotemporal Dementia Despite increasing Progranulin Expression - NeurologyLive, accessed June 19, 2025, https://www.neurologylive.com/view/latozinemab-shows-no-impact-disease-progression-c9orf72-frontotemporal-dementia-increasing-progranulin-expression
  47. Latozinemab - DDrare: Database of Drug Development for Rare Diseases, accessed June 19, 2025, https://ddrare.nibn.go.jp/cgi-bin/drug_who_e.cgi?query=Latozinemab&disease_id=127
  48. Phase 3 INFRONT-3 Study Details Baseline Characteristics of Participants With FTD-GRN, accessed June 19, 2025, https://www.neurologylive.com/view/phase-3-infront-3-study-details-baseline-characteristics-participants-ftd-grn
  49. Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005) - Neurology.org, accessed June 19, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000211441
  50. A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) - ClinicalTrials.Veeva, accessed June 19, 2025, https://ctv.veeva.com/study/a-phase-3-study-to-evaluate-efficacy-and-safety-of-al001-in-frontotemporal-dementia-infront3
  51. INFRONT-3 - Barrow Neurological Institute, accessed June 19, 2025, https://www.barrowneuro.org/patient-care/take-action/find-a-clinical-trial/clinical-trial/a-phase-3-study-to-evaluate-efficacy-and-safety-of-al001-in-frontotemporal-dementia-infront-3/
  52. A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) | Clinical Research Trial Listing - CenterWatch, accessed June 19, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT04374136/a-phase-3-study-to-evaluate-efficacy-and-safety-of-al001-in-frontotemporal-dementia-infront-3
  53. Alector announces completion of enrolment in INFRONT-3 trial of latozinemab for frontotemporal dementia | Alzheimer Europe, accessed June 19, 2025, https://www.alzheimer-europe.org/news/alector-announces-completion-enrolment-infront-3-trial-latozinemab-frontotemporal-dementia?language_content_entity=en
  54. Baseline Characteristics for INFRONT-3: A Phase 3, Double-Blind, Placebo-Controlled, 96-Week Study Evaluating Latozinemab in FTD - Investors | Alector, accessed June 19, 2025, https://investors.alector.com/static-files/b3aac9de-df7d-4ff8-93cc-43a8abcf3987
  55. INFRONT-3 - Alzheimer Europe, accessed June 19, 2025, https://www.alzheimer-europe.org/research/clinical-trials/infront-3?language_content_entity=en
  56. Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) - GlobeNewswire, accessed June 19, 2025, https://www.globenewswire.com/news-release/2024/09/19/2948953/0/en/Alector-Presents-Baseline-Characteristics-for-Pivotal-INFRONT-3-Phase-3-Clinical-Trial-at-the-14th-International-Conference-on-Frontotemporal-Dementias-ISFTD-2024.html
  57. FDA Grants Breakthrough Therapy Designation to Experimental FTD Therapy | AFTD, accessed June 19, 2025, https://www.theaftd.org/posts/1ftd-in-the-news/b-breakthrough-therapy-grn/
  58. Alector Reports First Quarter 2025 Financial Results and Provides Business Update, accessed June 19, 2025, https://investors.alector.com/news-releases/news-release-details/alector-reports-first-quarter-2025-financial-results-and/
  59. Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire, accessed June 19, 2025, https://www.globenewswire.com/news-release/2025/02/26/3033325/0/en/Alector-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html
  60. Alector Reports First Quarter 2025 Financial Results and Provides Business Update, accessed June 19, 2025, https://www.globenewswire.com/news-release/2025/05/08/3077697/0/en/Alector-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Update.html
  61. Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025 - Stock Titan, accessed June 19, 2025, https://www.stocktitan.net/news/ALEC/alector-reports-on-recent-progress-and-outlines-strategic-priorities-svse7w63gxl1.html
  62. Form 8-K for Alector INC filed 05/08/2025, accessed June 19, 2025, https://investors.alector.com/static-files/4626dc63-6514-470b-8b68-9e17b8354226
  63. Alector Provides Executive Leadership Update, accessed June 19, 2025, https://investors.alector.com/news-releases/news-release-details/alector-provides-executive-leadership-update-1/
  64. Alector Provides Executive Leadership Update, accessed June 19, 2025, https://investors.alector.com/news-releases/news-release-details/alector-provides-executive-leadership-update-0/
  65. Latozinemab: A Promising Treatment for Neurodegenerative Diseases - Clinical trials, accessed June 19, 2025, https://clinicaltrials.eu/inn/latozinemab/
  66. Continuation Study for Latozinemab - Mayo Clinic, accessed June 19, 2025, https://www.mayo.edu/research/clinical-trials/cls-20583640?p=1
  67. Expanded Access Program Policy - Lantheus, accessed June 19, 2025, https://www.lantheus.com/expanded-access-program-policy/
  68. Expanded Access Policy - Larimar Therapeutics, accessed June 19, 2025, https://larimartx.com/our-programs/expanded-access-policy/
  69. Frontotemporal Dementia (FTD) Clinical Program - Denali Therapeutics, accessed June 19, 2025, https://www.denalitherapeutics.com/patient-community/frontotemporal-dementia-ftd
  70. Frontotemporal Dementia Pipeline Insight - DelveInsight, accessed June 19, 2025, https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight
  71. Progranulin Clinical Trials 2022: Studies Targeting the GRN Gene at Forefront of Research, accessed June 19, 2025, https://ftdregistry.org/press/progranulin-clinical-trials-2022-studies-targeting-the-grn-gene-at-forefront-of-research/
  72. News - Progranulin Navigator, accessed June 19, 2025, https://www.progranulinnavigator.org/resources/news
  73. About upliFT-D | A Clinical Trial for Frontotemporal Dementia, accessed June 19, 2025, https://passagebioclinicaltrials.com/Frontotemporal-Dementia/en/about-this-trial
  74. Progranulin Clinical Trials Directory | Find Research Studies & Genetic Testing Opportunities, accessed June 19, 2025, https://www.progranulinnavigator.org/directory
  75. FEATURED STUDY: PROCLAIM - A Study of PR006 with FTD-GRN, accessed June 19, 2025, https://ftdregistry.org/press/featured-study-proclaim-a-study-of-pr006-with-ftd-grn/
  76. Lilly Announces Agreement to Acquire Prevail Therapeutics | Eli Lilly and Company, accessed June 19, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-announces-agreement-acquire-prevail-therapeutics
  77. Arkuda Therapeutics Secures Funding for FTD-GRN Research | AFTD, accessed June 19, 2025, https://www.theaftd.org/posts/1ftd-in-the-news/arkuda-therapeutics-secures-funding-for-ftd-grn-research/
  78. Arkuda Therapeutics to Present Update on ARKD-104, its First-in-Class Oral Development Candidate for the Treatment of Frontotemporal Dementia and other Neurodegenerative Disorders at the Alzheimer's Association International Conference 2023, accessed June 19, 2025, https://www.prnewswire.com/news-releases/arkuda-therapeutics-to-present-update-on-arkd-104-its-first-in-class-oral-development-candidate-for-the-treatment-of-frontotemporal-dementia-and-other-neurodegenerative-disorders-at-the-alzheimers-association-international-confe-301879066.html
  79. Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates, accessed June 19, 2025, https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2025/Passage-Bio-Announces-Interim-Data-from-upliFT-D-Study-in-FTD-GRN-and-Provides-Business-Updates/default.aspx
  80. Denali and Takeda Open FTD-GRN Clinical Trial Site at UPenn | AFTD, accessed June 19, 2025, https://www.theaftd.org/posts/1ftd-in-the-news/b-denalitakeda-upenn-ftd-grn/
  81. Vesper Bio Clinical Trial for FTD-GRN Enters Phase Ib/IIa | AFTD, accessed June 19, 2025, https://www.theaftd.org/posts/1ftd-in-the-news/blog-vesper-bio-ftd-grn-ibiia/
  82. Lilly nabs gene therapy company Prevail Therapeutics | CPHI Online, accessed June 19, 2025, https://www.cphi-online.com/news/lilly-nabs-gene-therapy-company-prevail-therapeutics/
  83. Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights, accessed June 19, 2025, https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2025/Passage-Bio-Reports-First-Quarter-2025-Financial-Results-and-Provides-Recent-Business-Highlights/default.aspx
  84. ARKD-104 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 19, 2025, https://synapse.patsnap.com/drug/9008f75b6191420c8a45376cdb09120a
  85. The road ahead: 2025 (part 1) - The Science of Parkinson's, accessed June 19, 2025, https://scienceofparkinsons.com/2025/01/01/ra2025-1/
  86. Frontal Temporal Dementia (FTD) Active Not Recruiting Phase 3 Trials for Latozinemab (DB16978) - DrugBank, accessed June 19, 2025, https://go.drugbank.com/indications/DBCOND0069563/clinical_trials/DB16978?phase=3&status=active_not_recruiting
  87. Arkuda launches to tackle neuro diseases - ACS Publications - American Chemical Society, accessed June 19, 2025, https://pubs.acs.org/doi/10.1021/cen-09744-buscon2
  88. Arkuda Therapeutics raises USD64 million in financing to test a new small molecule therapeutic for frontotemporal dementia in 2023 | Alzheimer Europe, accessed June 19, 2025, https://www.alzheimer-europe.org/news/arkuda-therapeutics-raises-usd64-million-financing-test-new-small-molecule-therapeutic?language_content_entity=en
  89. Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin (FTD-GRN) - BioSpace, accessed June 19, 2025, https://www.biospace.com/denali-therapeutics-announces-initiation-of-phase-1-2-clinical-trial-of-dnl593-ptv-pgrn-for-frontotemporal-dementia-granulin-ftd-grn
  90. Preclinical Research Shows Promising New Way to Increase Progranulin in the Brain, accessed June 19, 2025, https://ftdregistry.org/press/preclinical-research-shows-promising-new-way-to-increase-progranulin-in-the-brain/
  91. Frontotemporal Dementia Market Size to Reach US$ 688.2 Million by 2035, Impelled by Advancements in Diagnostics and Expanding Research & Development - BioSpace, accessed June 19, 2025, https://www.biospace.com/press-releases/frontotemporal-dementia-market-size-to-reach-us-688-2-million-by-2035-impelled-by-advancements-in-diagnostics-and-expanding-research-development
  92. Frontotemporal Dementia Market | Key Companies, Therapies - DelveInsight, accessed June 19, 2025, https://www.delveinsight.com/report-store/frontotemporal-dementia-market
  93. Latozinemab (AL001): Alector's Wholly-owned Humanized Recombinant Monoclonal Antibody - Emerging Drug Insights and Market Forecasts 2019-2022 & 2023-2032 - GlobeNewswire, accessed June 19, 2025, https://www.globenewswire.com/news-release/2023/04/13/2646435/0/en/Latozinemab-AL001-Alector-s-Wholly-owned-Humanized-Recombinant-Monoclonal-Antibody-Emerging-Drug-Insights-and-Market-Forecasts-2019-2022-2023-2032.html
  94. Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Market Chameleon, accessed June 19, 2025, https://marketchameleon.com/PressReleases/i/2053626/ALEC/alector-reports-fourth-quarter-and-full-year
  95. Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Stock Titan, accessed June 19, 2025, https://www.stocktitan.net/news/ALEC/alector-reports-fourth-quarter-and-full-year-2024-financial-results-z5yx7nb9mg6x.html
  96. Alector, Inc. SEC 10-K Report - TradingView, accessed June 19, 2025, https://www.tradingview.com/news/tradingview:3b0245bdc4eb5:0-alector-inc-sec-10-k-report/
  97. AL101 - PGRN – Neurodegenerative diseases - Alector, accessed June 19, 2025, https://alector.com/candidates/al101-pgrn-neurodegenerative-diseases/
  98. Alector concludes enrolment in Phase II trial of Alzheimer's treatment - Clinical Trials Arena, accessed June 19, 2025, https://www.clinicaltrialsarena.com/news/alector-concludes-enrolment-trial/
  99. Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease - GlobeNewswire, accessed June 19, 2025, https://www.globenewswire.com/news-release/2025/04/17/3063333/0/en/Alector-Announces-Completion-of-Enrollment-in-the-PROGRESS-AD-Phase-2-Clinical-Trial-of-AL101-GSK4527226-in-Individuals-with-Early-Alzheimer-s-Disease.html
  100. Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease, accessed June 19, 2025, https://investors.alector.com/news-releases/news-release-details/alector-announces-first-patient-dosed-progress-ad-phase-2/
  101. Progranulin FTD Resources | Support, Genetic Testing & Clinical Trials Information, accessed June 19, 2025, https://www.progranulinnavigator.org/resources
  102. Passage Bio Announces Interim Data for UpliFT-D Trial for FTD-GRN | AFTD, accessed June 19, 2025, https://www.theaftd.org/posts/1ftd-in-the-news/blog-passage-bio-uplift-d-updt/
  103. Find A Study - FTD Disorders Registry, accessed June 19, 2025, https://ftdregistry.org/find-a-study/
  104. Frontotemporal Dementia Research Program - Vanderbilt University Medical Center |, accessed June 19, 2025, https://www.vumc.org/ftdclinic/frontotemporal-dementia-research-program
  105. Studies Seeking Participants | AFTD, accessed June 19, 2025, https://www.theaftd.org/research-clinical-trials/featured-studies/
  106. Clinical Trial Evaluating Investigational AVB-101 in Patients With FTD - YouTube, accessed June 19, 2025, https://www.youtube.com/watch?v=O3i9qSUDhZs
  107. Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease - Stock Titan, accessed June 19, 2025, https://www.stocktitan.net/news/ALEC/alector-announces-completion-of-enrollment-in-the-progress-ad-phase-rx32vto7lscu.html
  108. Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025, accessed June 19, 2025, https://investors.alector.com/node/10126/pdf

Published at: June 19, 2025

This report is continuously updated as new research emerges.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.